Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.

To assess safety and efficacy of amivantamab plus monochemotherapy in terms of ORR, PFS and OS in subjects with EGFR exon20 insertion mutations metastatic non-small cell lung cancer unfit for platinum-based chemotherapy.

Trial Details

NCT ID
NCT07392658
Phase
PHASE2
Sponsor
Fondazione Ricerca Traslazionale
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Amivantamab
Locations (sample)
  • Roma, Roma (RM), Italy|44.99364,11.10642

Key Eligibility Criteria

  • Written informed consent;
  • Male or female patient aged ≥18 years;
  • Histologically or cytologically confirmed stage IV or recurrent non-squamous NSCLC harboring EGFR exon20 insertion mutation;
  • No prior systemic treatment;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →